CD19 and acute lymphoblastic leukemia: In 2017, the first CAR T-cell therapy, Tisagenlecleucel, was approved by the United States Food and Drug Administration (FDA) for the treatment of patients ≤25 years of age with R/R CD19+ B-cell acute lymphoblastic leukemia (B-ALL) who have experienced a second or greater relapse [5].